A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis

银屑病面积及严重程度指数 医学 银屑病 临床终点 皮肤科生活质量指数 临床试验 疾病严重程度 红斑 生活质量(医疗保健) 随机对照试验 皮肤病科 内科学 护理部
作者
Christopher S. Carlin,Steven R. Feldman,James G. Krueger,Alan Menter,Gerald G. Krueger
出处
期刊:Journal of The American Academy of Dermatology [Elsevier BV]
卷期号:50 (6): 859-866 被引量:339
标识
DOI:10.1016/j.jaad.2003.09.014
摘要

A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis. Many consider this endpoint to be too stringent as it places potentially useful therapies at risk of failing to demonstrate efficacy. We hypothesized that a 50% reduction in the PASI score (PASI 50) represents a meaningful change in a person's life and thus is a better primary endpoint. To test this hypothesis, we analyzed PASI scores, quality of life (QoL) data, and desired re-treatment scores from a number of clinical trials in addition to studying individual elements that make up the PASI. This analysis shows (1). the PASI score is not linearly reflective of psoriasis severity (eg, a reduction in area of 95% without a change in redness, scaliness, and induration translates to only a 66% reduction in PASI); conversely, a drop in erythema, scale, and induration from an average of 3 to 1 would not lead to a 75% reduction in PASI; (2). treatment with methotrexate, an effective psoriasis therapy, more frequently reaches PASI 50 than PASI 75 as evidenced by a recent open trial in which 63% of patients achieved PASI 50 versus 26% achieving PASI 75; (3). improvement in QoL exists at PASI 50, using the Dermatology Quality of Life Index, as documented in several recently completed large clinical trials; (4). patients achieving PASI 75 frequently defer therapy until they are well below PASI 50; a clinical trial where retreatment was patient initiated showed patients did not re-treat until their PASI dropped to an average of 20% improvement from baseline; and (5). effective, meaningful therapies are consistently differentiated from placebo at PASI 50 as evidenced by histologic and photographic parameters of clinical trials of alefacept, efalizumab, and etanercept. We conclude that PASI 50 equates to a clinically meaningful improvement in psoriasis and represents a discerning primary endpoint.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
果子大王发布了新的文献求助30
1秒前
吃猫的鱼发布了新的文献求助10
2秒前
cora完成签到,获得积分10
2秒前
荼蘼发布了新的文献求助10
2秒前
时尚愚志发布了新的文献求助10
3秒前
3秒前
盈缺完成签到,获得积分10
3秒前
3秒前
4秒前
4秒前
深情安青的应助被木田采纳,获得10
4秒前
pyb0919发布了新的文献求助10
4秒前
侯赛因发布了新的文献求助10
5秒前
科研通AI6.3的应助被我爱学习采纳,获得10
5秒前
aw发布了新的文献求助10
6秒前
7秒前
7秒前
8秒前
小聋包完成签到,获得积分10
8秒前
9秒前
Rongxing完成签到 ,获得积分10
9秒前
9秒前
10秒前
小蘑菇的应助被xucc采纳,获得10
10秒前
理想完成签到,获得积分10
11秒前
11秒前
11秒前
12秒前
GamAooL发布了新的文献求助10
13秒前
13秒前
啦啦啦完成签到 ,获得积分10
14秒前
Iriss完成签到 ,获得积分10
14秒前
14秒前
行走的荷尔蒙的应助被依山尽采纳,获得30
15秒前
ZYP完成签到,获得积分10
15秒前
科目三的应助被小棕瓶采纳,获得10
15秒前
revo完成签到,获得积分10
16秒前
温暖大米完成签到,获得积分20
16秒前
酷炫的金鱼完成签到 ,获得积分10
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175262
求助须知:如何正确求助?哪些是违规求助? 9567017
关于积分的说明 21789663
捐赠科研通 7769695
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556124
邀请新用户注册赠送积分活动 2477241